News

Seal Rock Therapeutics to Present Preclinical Efficacy Findings for SRT-015 in Cholestatic Liver Diseases at the European Association for Study of the Liver (EASL) Congress 2024

Seal Rock Therapeutics Announces Out-Licensing Agreement with
GENFIT for Development of Injectable Formulation of SRT-015 for Acute on Chronic Liver Disease (ACLF)

Seal Rock Therapeutics Receives Small Business Innovation Research Grant from National Institutes of Health to Support Novel Therapy for Acute Alcoholic Hepatitis

Seal Rock Therapeutics Receives Grant from U.S. Army Medical Research Acquisition Activity to Support ALS Research Program

Seal Rock Says Parkinson’s Therapy SRT-055 Shows Promise in Lab

Seal Rock Therapeutics to Present at Biotech Showcase 2023

Seal Rock Therapeutics Announces Upcoming Oral and Poster Presentations at AASLD’s The Liver Meeting^® 2022

Seal Rock Therapeutics Announces Completion of Single Ascending Dose Cohort in Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH

Seal Rock Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting^® 2020

Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in NASH